hrp0095p1-180 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

The lifetime cost of reproductive potential – who spends the most?

Fuchs Shai , Goldenfeld Miki , Dviri Michal , Librach Clifford , Baum Micha

Objectives: To determine who spends more energy over a lifetime on maintaining their reproductive potential: men or women?Design: As a model and energetic equivalent, we set the mass of gametes supported over time from birth until exhaustion of fertility. We calculated gender-specific dynamics of gamete pool mass over time. To this purpose we collated data from existing literature, accounting for gamete volume over stage...

hrp0089p2-p411 | Thyroid P2 | ESPE2018

Awareness of the Risks of Acquired Iodine Deficiency in Strict Vegan Diets

Brandt Agnieszka , Cheung Moira , Sakka Sophia , Ajzensztejn Michal , Hulse Tony

Background: Iodine deficiency is the most common cause of acquired hypothyroidism worldwide but rare in developed countries. Incidence of iodine deficiency may be rising due to increased popularity of vegan diets. There is minimal information on official health promotional webpages alerting to this risk.Case presentation: We present a 2.5yr old boy and his 6yr old sister from a family who adhere to a strict vegan diet and additional dietary restriction i...

hrp0086p1-p615 | Growth P1 | ESPE2016

Immunogenicity Results of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): A Phase 2 Study in Children with Growth Hormone Deficiency

Mendelson Michal Jaron , Bar-Ilan Ahuva , Hershkovitz Oren , Hart Gili

Background: CTP-modified hGH (MOD-4023) has been developed for once weekly administration in GH deficient (GHD) adults and children. Immunogenicity samples of once-weekly s.c. administration of MOD-4023 were detected for the presence of binding and neutralizing anti-MOD-4023 Ab’s in pediatric Phase 2 study.Objective and hypotheses: During the first year of the study, 53 pre-pubertal GHD children were treated with once-weekly s.c. injections of one o...

hrp0086p2-p964 | Thyroid P2 | ESPE2016

An Unusual Complication of Graves’ Disease

Adesokan Akintayo , Vigneswaran Trisha , Mathur Sujeev , Cheung Moira , Ajzensztejn Michal

Background: Atrioventricular (AV) conduction defects are rare but significant complications of hyperthyroidism. Beta-blockers and co-existent infection further increase the risk of such conduction abnormalities.Objective and hypotheses: We report the case of a 10-year old girl treated for tachycardia and hypertension associated with hyperthyroidism who developed symptomatic 2:1 heart block.Method: Our patient presented with a histo...

hrp0084p3-1134 | Puberty | ESPE2015

Paraphilic Compulsion Secondary to Dopamine Replacement Therapy and Successful Treatment with GnRH Analogues

Brewka Anna , Owen Tamsin , Lin Jean-Pierre , Ajzensztejn Michal

Background: Hypersexualized behaviour in the paediatric population is a rare phenomenon. The aetiology of paraphilia is not completely understood, but some studies suggest imbalance of the dopamine serotonin system. Paraphilia has also been described as a side-effect of treatment with monoaminooxidase inhibitors (MAOI) and dopamine agonists. Most of the currently used pharmacologic treatments of the paraphilias have serotonin and testosterone/dihydrotestosterone as their targe...

hrp0094wg3.3 | ESPE Working Group on Diabetes Technology (DT) Symposium | ESPE2021

The impact of fear of hyperglycemia in parents of children with type 1 diabetes mellitus on overall glycemic control

Liberman Alon , Nevo-Schenker Michal , Sachar-Lavie Iris , Phillip Moshe ,

Background: Achieving proper glycemic control is the major goal in the management of type 1 diabetes. The Diabetes Control and Complication Trial showed that optimal glycemic control can decrease micro- and macrovascular complications in adolescents and adults with type 1 diabetes. Both hypo and hyperglycemia affect crucial regions in the developing brain. In children and young adolescents, most of the work towards achieving optimal glycemic control is led by ...

hrp0084p3-1187 | Thyroid | ESPE2015

The Benefits of Preterm Neonate Development by Early Replacement Therapy with Levothyroxine: Longitudinal Prospective Study

Ben-Skowronek Iwona , Wisniowiecka Magdalena

Background: In premature neonates hypothyroidism or thyroid sick syndrome is frequently diagnosed, which is a result of the immaturity of the gland itself and the hypothalamic–pituitary–thyroid axis. The necessity of rapid adaptation to extrauterine life, generation of high thermal energy, and accelerated development of the central nervous system is the cause of the increased demand for thyroid hormone.Objective and hypotheses: The aim of our s...

hrp0095p2-53 | Diabetes and Insulin | ESPE2022

Clinical and immunological characteristics of new-onset type 1 diabetes in children during the COVID-19 pandemic

Gil Margolis Merav , Weizman Sarit , Lazar Liora , Yakobovich-Gavan Michal , Tenenbaum Ariel , Phillip Moshe , Oron Tal

Background: Type 1 Diabetes (T1D) is a chronic disease resulting from autoimmune destruction of insulin-secreting pancreatic β cells. Viruses are known to play a role in the pathogenesis of T1D. There is no consistent evidence that SARS-CoV-2 induces T1D in children or adults. Nevertheless, evidence suggests that the SARS-CoV-2 affects β cell function, suggesting a role for the virus in the pathogenesis of the disease. It is thus plausible that the e...

hrp0089p1-p041 | Diabetes & Insulin P1 | ESPE2018

Concealment of Type 1 Diabetes in Adolescence Affects Adherence to Treatment, Metabolic Control, and Quality of Life

Nir Judith , Leffler Nir , Nagelberg Nessia , Yacobovitz-Gavan Michal , Phillip Moshe , Oron Tal

Introduction: Type 1 diabetes (T1D) is one of the common chronic diseases of childhood. T1D management is affected both by physiological and behavioral factors. Some patients and their parents choose to conceal the disease from others. Concealment of disease status is not unique for T1D, and has been shown to adversely affect clinical outcomes, social support and well-being of patients with other chronic conditions. There is limited data on the effects of concealment of T1D in...

hrp0086rfc8.5 | Growth: Clinical | ESPE2016

Optimal Sampling of IGF-1 During Weekly Administration of a Long Acting Human Growth Hormone (MOD 4023)

Fisher Dennis M. , Mendelson Michal Jaron , Vander Shelly , Koren Ronit , Hart Gili

Background: OPKO Biologics is developing MOD-4023, a long-acting growth hormone (GH), intended for weekly dosing for the treatment of idiopathic GH deficiency in children. At ESPE2015, we presented pharmacokinetic (PK) and pharmacodynamic (PD, based on IGF-1) models for weekly MOD-4023 administration in children aged 3–11 years. These models confirm that IGF-1 (and IGF-1 SDS) varies during the dosing interval. One critical clinical and research issue is when to optimally ...